Seattle, Washington – Nohla Therapeutics Inc. (Nohla), a biotechnology company pioneering the field of universal donor cellular therapies for treating patients with life threatening hematological disorders and cancers, today announced the initial closing of a $43.5M Series A financing round. [Read more…]
Hematopoietic Stem Cells (HSCs)
Cord Blood Market Trends, by Region and Sub-Segment
The cord blood market is a complex international industry, composed of public, private, and hybrid cord blood banks.
These market participants store a range of varied products, including cord blood, cord tissue, and sometimes, related perinatal tissues and stem cell types. Rates of cord blood utilization for clinical use vary substantially as well.
Therefore, our approach to analyzing cord blood market trends is to look at it geographically, as well as by sub-segment according to blood units banked, tissue units banked, and clinical units transplanted.
A high level assessment of cord blood market growth is that North American is flat, North Asia and Southeast Asia (SEA) are growing by double digits, and Europe is declining.
We summarize these cord blood industry trends as follows:
To learn more, read our recent interview with Kenneth Harris of CuraSense Advisors, in which we discuss growth rates and trends within the global cord blood banking industry.
BioInformant Market Insights Featured in AABB Cord Blood Banking Article
In October 2016, an AABB cord blood article titled “Family Cord Blood Banks Adapt to the Changing Business Landscape” was released by contributing writer Laura Fusco.
Throughout the article, BioInformant was honored to have our quotes included to support and explain the current business landscape for family cord blood banks.
Below is the introduction to the recent AABB cord blood article:
“The industry has matured a lot. There was a relatively strong growth period ten to fifteen years ago, but during the past five years, the market has matured and consolidated,” said Cade Hildreth, President and CEO of BioInformant.com, a stem cell market research firm. “The growth of the North American market has really leveled off. It’s not a bad thing though; the surviving participants are strong, generally well capitalized, and storing larger quantities of cord blood units under more standardized conditions.”
Other contributing quotes from BioInformant within the AABB cord blood article include:
In addition to tissue services, some cord blood banks are now offering banking for adipose-derived cells, placenta-derived stem cells and menstrual-derived stem cells. “With multiple income sources, the banks can distribute the cost per client across multiple services, and everyone gets more value for the money,” Hildreth said. “The lab equipment and expertise needed to store various stem cell types are similar, so there is a trend toward cord blood banks evolving into diversified stem cell biobanks.”
Hildreth also noted that all stem cell types are stored for the same purpose—use in regenerative medicine—but as biobanks, the businesses become positioned to benefit from progress with one stem cell type, while simultaneously protecting themselves against scientific or clinical issues that could arise with other cell types.” [Read more…]
Cell Care Australia Acquires Insception Lifebank in Canada
The largest cord blood bank in Australia, Cell Care, has announced that it is acquiring the largest cord blood bank in Canada, Insception Lifebank. This acquisition is part of a larger trend occurring within the cord blood banking industry, which is the trend of maturation and consolidation.
Over the past five years, the cord blood and tissue marketplace has undergone substantial consolidation. One major event was the acquisition of the United States’ largest cord blood, Cord Blood Registry (CBR), by AMAG Pharmaceuticals for $700M in March of 2015. Previously, ViaCord had been acquired by the multinational company PerkinElmer in October 2007 for $300M. [Read more…]
Nohla Therapeutics to Acquire Clinical Grade Cord Blood Units from LifeSouth for Expanded HSC Products
Nohla Therapeutics has signed an exclusive supply agreement with LifeSouth Community Blood Centers headquartered in Gainesville, Florida. Under this agreement, LifeSouth’s cord blood banking program will supply Nohla Therapeutics with clinical grade cord blood units that will be used in the production process for the Company’s expanded hematopoietic stem and progenitor cell (HSC/HPC) products. [Read more…]
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 27
- Next Page »